Can a simple supplement slow ALS? new study investigates
NCT ID NCT04562831
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a combination of nicotinamide (a form of vitamin B3) and pterostilbene (a plant compound) can slow the progression of ALS, a fast-moving nerve disease. About 380 adults with ALS will take either the supplement or a placebo for a period of time. The goal is to see if the treatment helps maintain muscle function and improve survival and quality of life.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Akershus University Hospital
Lørenskog, Norway
-
Haukeland University Hospital
Bergen, Norway
-
Helse Fonna HF
Haugesund, Norway
-
Helse Førde HF
Førde, Norway
-
Oslo University Hospital
Oslo, Norway
-
St.Olavs Hospital HF
Trondheim, Norway
-
Stavanger University Hospital
Stavanger, Norway
-
Universitetssykehuset Nord-Norge
Tromsø, Norway
-
Vestre Viken HF
Drammen, Norway
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new rowing seat help veterans with paralysis row freely?
- Can filtering the blood slow ALS in patients with a rogue antibody?
- Custom-Made genetic drug takes aim at rare form of ALS
- Tailored genetic drug takes aim at a rare form of ALS
- Custom-Made genetic drug takes aim at rare form of ALS
- Spinal cord cell transplant aims to slow ALS